Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.42
VRTX's Cash to Debt is ranked lower than
76% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. VRTX: 1.42 )
Ranked among companies with meaningful Cash to Debt only.
VRTX' s 10-Year Cash to Debt Range
Min: 0.92  Med: 2.36 Max: 26.61
Current: 1.42
0.92
26.61
Equity to Asset 0.45
VRTX's Equity to Asset is ranked lower than
74% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. VRTX: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
VRTX' s 10-Year Equity to Asset Range
Min: -0.02  Med: 0.50 Max: 0.95
Current: 0.45
-0.02
0.95
F-Score: 3
Z-Score: 12.22
M-Score: -1.70
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -108.02
VRTX's Operating margin (%) is ranked lower than
55% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -71.51 vs. VRTX: -108.02 )
Ranked among companies with meaningful Operating margin (%) only.
VRTX' s 10-Year Operating margin (%) Range
Min: -602.63  Med: -127.43 Max: 8.07
Current: -108.02
-602.63
8.07
Net-margin (%) -117.36
VRTX's Net-margin (%) is ranked lower than
57% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. VRTX: -117.36 )
Ranked among companies with meaningful Net-margin (%) only.
VRTX' s 10-Year Net-margin (%) Range
Min: -630.27  Med: -114.19 Max: 2.1
Current: -117.36
-630.27
2.1
ROE (%) -62.80
VRTX's ROE (%) is ranked lower than
69% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. VRTX: -62.80 )
Ranked among companies with meaningful ROE (%) only.
VRTX' s 10-Year ROE (%) Range
Min: -180.27  Med: -37.78 Max: 4.58
Current: -62.8
-180.27
4.58
ROA (%) -31.40
VRTX's ROA (%) is ranked lower than
55% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. VRTX: -31.40 )
Ranked among companies with meaningful ROA (%) only.
VRTX' s 10-Year ROA (%) Range
Min: -58.14  Med: -25.55 Max: 1.51
Current: -31.4
-58.14
1.51
ROC (Joel Greenblatt) (%) -90.05
VRTX's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. VRTX: -90.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
VRTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1092.55  Med: -167.78 Max: 96.25
Current: -90.05
-1092.55
96.25
Revenue Growth (3Y)(%) -28.50
VRTX's Revenue Growth (3Y)(%) is ranked lower than
74% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. VRTX: -28.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
VRTX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -32.4  Med: 8.10 Max: 130.2
Current: -28.5
-32.4
130.2
» VRTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

VRTX Guru Trades in Q2 2014

Paul Tudor Jones 2,178 sh (New)
Ken Fisher 6,753 sh (New)
Vanguard Health Care Fund 11,807,500 sh (+1.54%)
Steven Cohen 934,700 sh (unchged)
John Burbank Sold Out
Jim Simons Sold Out
George Soros Sold Out
Pioneer Investments 850,152 sh (-28.91%)
» More
Q3 2014

VRTX Guru Trades in Q3 2014

Stanley Druckenmiller 146,600 sh (New)
Paul Tudor Jones 7,726 sh (+254.73%)
Vanguard Health Care Fund 11,807,500 sh (unchged)
Pioneer Investments 661,813 sh (unchged)
Ken Fisher 4,593 sh (-31.99%)
Steven Cohen 443,300 sh (-52.57%)
» More
Q4 2014

VRTX Guru Trades in Q4 2014

Andreas Halvorsen 764,200 sh (New)
Stanley Druckenmiller Sold Out
Pioneer Investments 647,257 sh (-2.20%)
Ken Fisher 4,378 sh (-4.68%)
Paul Tudor Jones 6,589 sh (-14.72%)
Vanguard Health Care Fund 9,808,860 sh (-16.93%)
Steven Cohen 16,500 sh (-96.28%)
» More
Q1 2015

VRTX Guru Trades in Q1 2015

Louis Moore Bacon 97,500 sh (New)
George Soros 56,912 sh (New)
Lee Ainslie 524,867 sh (New)
Jim Simons 159,317 sh (New)
Andreas Halvorsen 1,770,150 sh (+131.63%)
Steven Cohen 29,200 sh (+76.97%)
Pioneer Investments 794,247 sh (+22.71%)
Ken Fisher 4,386 sh (+0.18%)
Paul Tudor Jones Sold Out
Vanguard Health Care Fund 9,533,911 sh (-2.80%)
» More
» Details

Insider Trades

Latest Guru Trades with VRTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 28.74
VRTX's Forward P/E is ranked lower than
64% of the 168 Companies
in the Global Biotechnology industry.

( Industry Median: 23.42 vs. VRTX: 28.74 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 31.48
VRTX's P/B is ranked lower than
95% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. VRTX: 31.48 )
Ranked among companies with meaningful P/B only.
VRTX' s 10-Year P/B Range
Min: 5.79  Med: 12.25 Max: 37
Current: 31.48
5.79
37
P/S 49.95
VRTX's P/S is ranked lower than
74% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 14.66 vs. VRTX: 49.95 )
Ranked among companies with meaningful P/S only.
VRTX' s 10-Year P/S Range
Min: 4.47  Med: 18.72 Max: 80.48
Current: 49.95
4.47
80.48
Current Ratio 4.49
VRTX's Current Ratio is ranked higher than
51% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. VRTX: 4.49 )
Ranked among companies with meaningful Current Ratio only.
VRTX' s 10-Year Current Ratio Range
Min: 1.73  Med: 4.51 Max: 30.95
Current: 4.49
1.73
30.95
Quick Ratio 4.38
VRTX's Quick Ratio is ranked higher than
52% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. VRTX: 4.38 )
Ranked among companies with meaningful Quick Ratio only.
VRTX' s 10-Year Quick Ratio Range
Min: 1.62  Med: 4.51 Max: 30.95
Current: 4.38
1.62
30.95
Days Inventory 132.49
VRTX's Days Inventory is ranked lower than
55% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. VRTX: 132.49 )
Ranked among companies with meaningful Days Inventory only.
VRTX' s 10-Year Days Inventory Range
Min: 62.49  Med: 113.91 Max: 254.87
Current: 132.49
62.49
254.87
Days Sales Outstanding 48.83
VRTX's Days Sales Outstanding is ranked higher than
64% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. VRTX: 48.83 )
Ranked among companies with meaningful Days Sales Outstanding only.
VRTX' s 10-Year Days Sales Outstanding Range
Min: 25.75  Med: 47.06 Max: 106.15
Current: 48.83
25.75
106.15

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 181.24
VRTX's Price/Net Current Asset Value is ranked lower than
98% of the 572 Companies
in the Global Biotechnology industry.

( Industry Median: 8.11 vs. VRTX: 181.24 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
VRTX' s 10-Year Price/Net Current Asset Value Range
Min: 2.35  Med: 12.93 Max: 1835.5
Current: 181.24
2.35
1835.5
Price/Tangible Book 33.83
VRTX's Price/Tangible Book is ranked lower than
94% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. VRTX: 33.83 )
Ranked among companies with meaningful Price/Tangible Book only.
VRTX' s 10-Year Price/Tangible Book Range
Min: 2.13  Med: 9.29 Max: 122.26
Current: 33.83
2.13
122.26
Price/Median PS Value 2.74
VRTX's Price/Median PS Value is ranked lower than
82% of the 548 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. VRTX: 2.74 )
Ranked among companies with meaningful Price/Median PS Value only.
VRTX' s 10-Year Price/Median PS Value Range
Min: 0.28  Med: 1.12 Max: 4.16
Current: 2.74
0.28
4.16
Earnings Yield (Greenblatt) (%) -2.10
VRTX's Earnings Yield (Greenblatt) (%) is ranked higher than
67% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. VRTX: -2.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VRTX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.4  Med: 3.70 Max: 5.3
Current: -2.1
1.4
5.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:VX1.Germany, VRTX.Mexico, 0QZU.UK,
Vertex Pharmaceuticals Inc was incorporated in 1989. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. It is focused on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and early-stage development programs. The Company has marketed KALYDECO (ivacaftor) since it was approved in 2012 for the treatment of certain patients with CF and is seeking approval to market lumacaftor in combination with ivacaftor in order to increase the number of patients with CF who would be eligible for treatment with the Company's drugs. It is engaged in a number of other research and early-stage development programs, including programs in the areas of oncology and neurology. The Company's two products are INCIVE (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus, or HCV, infection; and KALYDEC (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis, or CF, who genetic mutation in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene, which is referred to as the G551D mutation. INCIVEK is approved in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus, or HCV, infection. As the Company markets and sells its approved products and advances its drug candidates through clinical development toward commercialization, it continues to build and maintain its supply chain and quality assurance resources. It faces competition based on the safety and efficacy of its products and drug candidates, the timing and scope of regulatory approvals, the availability and cost of supply, marketing and sales capabilities, reimbursement coverage, price, patent protection and other factors. Its registered trademarks include Vertex, KALYDECO and INCIVEK. The research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, safety monitoring, record keeping, promotion, advertising, distribution and marketing of its products and drug candidates are subject to extensive regulation by United States and foreign governmental authorities.
» More Articles for VRTX

Headlines

Articles On GuruFocus.com
Lee Ainslie Adds 90 New Stocks to His Portfolio Within the First Quarter May 20 2015 
Analysts Confident That Vertex Pharmaceuticals' CF Drug Will Receive FDA Approval May 13 2015 
Fate Of Cystic Fibrosis Drug By Vertex Is Now Dependent On FDA Approval May 13 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
Weekly CFO Sells Highlight: Texas Instruments Inc, Royal Caribbean Cruises Ltd, Vertex Pharmaceutica Nov 09 2014 
Weekly CFO Sells Highllight: Facebook Inc, Vertex Pharmaceuticals Inc, Nike Inc. Oct 05 2014 
Vanguard Health Care Fund Buys Vertex Pharmaceuticals, Zoetis Inc, , Sells Cerner Corporation, AbbVi Aug 02 2013 
Weekly Guru Bargains Highlights: MBI, VRTX, GRPN, PBI, PC Dec 16 2012 
WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 21 2012 

More From Other Websites
Acquisitions May Fuel Gilead Sciences' Winning Ways Jun 26 2015
Here are the nine highest-paid life science executives in 2014 (BBJ photo gallery) Jun 26 2015
Biotech leads Nasdaq to fresh record close Jun 18 2015
Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors Jun 18 2015
Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors Jun 18 2015
VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Change in Directors or Principal Officers Jun 12 2015
Edited Transcript of VRTX presentation 11-Jun-15 4:20pm GMT Jun 12 2015
The Zacks Analyst Blog Highlights: Regeneron, Vertex, Celgene, Seattle Genetics and SAGE... Jun 11 2015
Vertex Announces Data Presentations at European Cystic Fibrosis Society (ECFS) Conference Jun 11 2015
Vertex Double Downs on Cystic Fibrosis Jun 10 2015
'Spending On These 10 Drugs Could Cost Taxpayers $50 Billion'--Is That Bad For Patients? Jun 10 2015
VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Entry into a Material Definitive Agreement Jun 09 2015
10 drugs to hit fed budget by $50B over decade Jun 08 2015
Vertex's $1B deal with Parion expands interest into other kinds of CF drugs Jun 08 2015
Durham's Parion inks deal that could exceed $1 billion Jun 08 2015
Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC)... Jun 04 2015
Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC)... Jun 04 2015
Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC)... Jun 04 2015
VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jun 04 2015
Vertex to Present at the Goldman Sachs Healthcare Conference on June 11 Jun 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK